Cochrane · systematic review · CD013720
Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline
Garegnani, L, Hyland, M, Roson Rodriguez, P, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
4
No studies
1
Included studies
NR
No studies 1 · 20%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 1 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyIdebenone compared to placebo in people with Duchenne muscular dystrophy and progressive respiratory decline
Population: people with Duchenne muscular dystrophy and progressive respiratory decline
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in respiratory function from baseline to 12 months, assessed by forced vital capacity (FVC) Assessed by: change from baseline in per cent of predicted values. Idebenone vs placebo | no estimate extracted | 1 study · 64 participants | Low Downgraded: imprecision, publication bias |
Hospitalisation due to respiratory infection Idebenone vs placebo | no estimate extracted | NR | No studies |
Quality of life Assessed by: Pediatric Quality of Life Inventory, change from baseline (0 to 100; 0 = worst outcome, 100 = best outcome) Idebenone vs placebo | no estimate extracted | 1 study · 63 participants | Moderate Downgraded: imprecision |
Serious adverse events Idebenone vs placebo | RR 0.42 [0.09, 2.04] | 1 study · 66 participants | Low Downgraded: imprecision, publication bias |
Non‐serious adverse events Idebenone vs placebo | RR 1 [0.88, 1.13] | 1 study · 66 participants | Low Downgraded: imprecision, publication bias |
Idebenone compared to placebo in people with Duchenne muscular dystrophy and progressive respiratory decline
Population: people with Duchenne muscular dystrophy and progressive respiratory decline
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in respiratory function from baseline to 12 months, assessed by forced vital capacity (FVC) Assessed by: change from baseline in per cent of predicted values. Idebenone vs placebo | no estimate extracted | 1 study · 64 participants | Low Downgraded: imprecision, publication bias |
Hospitalisation due to respiratory infection Idebenone vs placebo | no estimate extracted | NR | No studies |
Quality of life Assessed by: Pediatric Quality of Life Inventory, change from baseline (0 to 100; 0 = worst outcome, 100 = best outcome) Idebenone vs placebo | no estimate extracted | 1 study · 63 participants | Moderate Downgraded: imprecision |
Serious adverse events Idebenone vs placebo | RR 0.42 [0.09, 2.04] | 1 study · 66 participants | Low Downgraded: imprecision, publication bias |
Non‐serious adverse events Idebenone vs placebo | RR 1 [0.88, 1.13] | 1 study · 66 participants | Low Downgraded: imprecision, publication bias |